Ranolazine 500 mg
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Coronary Vascular Disease
Conditions
Atherosclerotic Coronary Vascular Disease
Trial Timeline
Mar 9, 2012 → Jan 2, 2014
NCT ID
NCT01562041About Ranolazine 500 mg
Ranolazine 500 mg is a phase 2 stage product being developed by Novartis for Atherosclerotic Coronary Vascular Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01562041. Target conditions include Atherosclerotic Coronary Vascular Disease.
What happened to similar drugs?
7 of 20 similar drugs in Atherosclerotic Coronary Vascular Disease were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01562041 | Phase 2 | Terminated |
Competing Products
20 competing products in Atherosclerotic Coronary Vascular Disease